Compare Cassava Sciences Inc (FLNA) vs Impinj Inc (PI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Impinj Inc — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Impinj Inc trades at $139.88 (market cap $4.40B). The key difference: Impinj Inc is far larger — about 82.8× Cassava Sciences Inc's market cap, and Impinj Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | PI | |
|---|---|---|
Market Cap | $53.14M | $4.40B |
Sector | Health | Technology |
52-Week High | $4.64 | $241.91 |
52-Week Low | $1.09 | $91.34 |
Enterprise Value | -$33.43M | $4.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Impinj (PI) trades at $141.42, down 2.2% today, with a bullish technical outlook supported by moving averages. The company maintains strong gross margins of 52.47% but faces profitability challenges with negative net income margins and ROE. Recent Q1 2026 earnings beat expectations, and analyst consensus remains strongly bullish with a $167.50 price target representing 18% upside potential.
While technical indicators and analyst sentiment support near-term upside, fundamental concerns persist with negative profitability metrics and elevated valuation ratios. Key risks include execution challenges in maintaining revenue growth amid competitive pressures and recent insider selling activity that may signal caution among major shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
